Dec 30, 2025 • MarketBeat
NEUTRAL
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $63.00 by Analysts at Jefferies Financial Group
Jefferies Financial Group has reduced its price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) from $114.00 to $63.00, while maintaining a "buy" rating. This adjustment follows the failure of Ultragenyx's experimental drug setrusumab in Phase 3 trials, leading to a significant stock plunge and planned company cutbacks. Despite the lowered price target, Jefferies still sees a potential upside of approximately 219% from the current share price for the biopharmaceutical company.
Dec 30, 2025 • Investing.com UK
BULLISH
Jefferies stock gets Buy rating reiterated by UBS on diversification strategy
UBS has reiterated a Buy rating on Jefferies Group (NYSE:JEF) with a price target of $76.00, representing a 21% upside from its current price. This endorsement comes as Jefferies expands its asset management business, including acquiring the remainder of Hildene, a move UBS views favorably for diversification and stable management fees. The company has also seen recent upgrades from Oppenheimer and Morgan Stanley, reflecting analyst confidence despite an ongoing SEC investigation.
Dec 28, 2025 • DC News Now
BEARISH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jefferies Financial Group Inc. - JEF
Pomerantz LLP is investigating Jefferies Financial Group Inc. (NYSE:JEF) concerning potential securities fraud and unlawful business practices. This investigation stems from reports that Jefferies' asset-management unit, Point Bonita Capital, is owed $715 million following the bankruptcy of auto supplier First Brands, and a subsequent SEC investigation into Jefferies' disclosure practices regarding its exposure to First Brands. The news led to a drop in Jefferies' stock price.
Dec 28, 2025 • MarketBeat
SOMEWHAT-BULLISH
20,763 Shares in Jefferies Financial Group Inc. $JEF Purchased by Brian Low Financial Group LLC
Brian Low Financial Group LLC recently acquired 20,763 shares of Jefferies Financial Group Inc. (NYSE:JEF) valued at approximately $1.36 million, making it their 21st largest holding. This purchase contributes to the 60.88% institutional ownership of the stock, alongside other major institutions increasing or initiating positions. Analysts currently rate JEF as a "Moderate Buy" with a consensus target price of $72.71, following the company's recent beat on quarterly earnings and revenue, and its consistent quarterly dividend.
Dec 27, 2025 • FOX40 News
BEARISH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jefferies Financial Group Inc. - JEF
Pomerantz LLP is investigating Jefferies Financial Group Inc. (NYSE:JEF) over potential securities fraud. This investigation follows reports that Jefferies' stock price fell significantly after news surfaced about an auto supplier, First Brands, filing for bankruptcy amid accounting questions and a subsequent Justice Department inquiry into the company and its dealings with creditors. Furthermore, the SEC is investigating Jefferies' relationship with First Brands and its disclosures to investors in its Point Bonita fund.
Dec 26, 2025 • MarketBeat
BULLISH
Covea Finance Buys Shares of 175,600 Jefferies Financial Group Inc. $JEF
Covea Finance has acquired a new stake of 175,600 shares in Jefferies Financial Group Inc. (NYSE:JEF), valued at approximately $11.49 million, during the third quarter, making up about 0.09% of the company. This comes as Jefferies exceeded third-quarter earnings expectations and maintains an average "Moderate Buy" analyst rating with an average price target of $72.71. Institutional investors collectively own 60.88% of Jefferies Financial Group's stock.